Gülsün Memi

Gülsün Memi

Auto-generated profile, based on publicly available information

Gülsün Memi

ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
ITİbRahim Türkel
İbRahim Türkel
GMGülsün Memi
Gülsün Memi
BYBurak Yazgan
Burak Yazgan
Spexin (SPX) is a 14 amino acid length peptide hormone which was discovered using bioinformatic tools. It is extensively expressed in central and peripheral tissues and secreted into circulation in response to metabolic stress. Recent studies revealed that SPX acts as a multifunctional peptide in various metabolic processes such as body weight, food intake, energy balance, glucose and lipid metabolism, lipid storage, salt–water balance, and arterial blood pressure. Endogenous SPX is sensitive to metabolic changes, and circulating levels of SPX have been shown to be reduced in chronic diseases such as obesity, diabetes, and insulin resistance. Moreover, in fish and rodent models, systemic SPX treatment has positive effects on metabolism including reduced food intake, fat mass, lipid accumulation, and inflammation, improved insulin sensitivity, energy expenditure, and organ functions which are underlying mechanisms in diseases. Taken together, these findings suggest that SPX is a potential drug target for the development of new pharmacological strategies to cure metabolic diseases. This review focuses on metabolo-protective properties of SPX and discusses novel insights into the biology and mechanism of SPX in the pathogenesis of diabetes, obesity, non-alcoholic fatty liver disease, metabolic syndrome, polycystic ovary syndrome, cardiovascular diseases, and kidney diseases, which are considerable global health problems.

1 October 2014 in Peptides
Verified
Journal Article
Closed access
MKMehmet Koç
Mehmet Koç
ZKZarife Nigar Özdemir Kumral
Zarife Nigar Özdemir Kumral
NÖNaziye Özkan
Naziye Özkan
GMGülsün Memi
Gülsün Memi
ÖKÖmer Kaçar
Ömer Kaçar
BYBerrak Yegen
Berrak Yegen

6 May 2026 in Nature
Verified
Journal Article
Open access
PDF file
EGElizabeth N. Godschall
Elizabeth N. Godschall
TGTaha Bugra Gungul
Taha Bugra Gungul
ISIsabelle R. Sajonia
Isabelle R. Sajonia
ABAleyna K. Buyukaksakal
Aleyna K. Buyukaksakal
OLOrien Li
Orien Li
AGAli Guler
Ali Guler
Glucagon-like peptide 1 receptor agonists (GLP1RAs) effectively reduce body weight and improve metabolic outcomes; however, established peptide-based therapies require injections and are complex to manufacture1,2,3. Small-molecule GLP1RAs promise oral bioavailability and scalable manufacturing, but their selective binding to human versus rodent receptors has limited mechanistic studies4,5,6,7,8,9. Here we developed humanized GLP1R mouse models to investigate how small-molecule GLP1RAs influence feeding behaviour. We found that these compounds regulate both homeostatic and hedonic feeding through parallel neural circuits. Beyond engaging canonical hypothalamic and hindbrain networks that control metabolic homeostasis, GLP1RAs recruit a discrete population of Glp1r-expressing neurons in the central amygdala, which selectively suppress the consumption of palatable foods by reducing dopamine release in the nucleus accumbens. Stimulating these central amygdalar neurons curtails hedonic feeding, whereas targeted deletion of the receptor in this cell population specifically diminishes the anorectic efficacy of GLP1RAs for reward-driven intake. These findings identify a neural circuit through which small-molecule GLP1RAs modulate reward processing, with implications for the treatment of substance-use disorder and binge eating.

1 June 2020 in Imaging
Verified
Journal Article
Open access
PDF file
LŞLeyla Semiha Şen
Leyla Semiha Şen
ZKZarife Nigar Özdemir Kumral
Zarife Nigar Özdemir Kumral
GMGülsün Memi
Gülsün Memi
FEFeriha Ercan
Feriha Ercan
BYBerrak Yegen
Berrak Yegen
CYCumhur Yeğen
Cumhur Yeğen
In order to investigate the role of the vagus nerve in the possible gastroprotective effect of obestatin on the indomethacin-induced acute oxidative gastric injury, Sprague-Dawley rats of both sexes were injected subcutaneously with indomethacin (25 mg/kg, 5% NaHCO3) followed by obestatin (10, 30 or 100 μg/kg). In other sets of rats, surgical vagotomy (Vx) or selective degeneration of vagal afferent fibers by perivagal capsaicin was performed before the injections of indomethacin or indomethacin + obestatin (30 μg/kg). Gastric serosal blood flow was measured, and 4 h after ulcer induction gastric tissue samples were taken for histological and biochemical assays. Obestatin reduced the severity of indomethacin-induced acute ulcer via the reversal of reactive hyperemia, by inhibiting ulcer-induced neutrophil infiltration and lipid peroxidation along with the replenishment of glutathione (GSH) stores, whereas Vx abolished the inhibitory effect of obestatin on blood flow and lipid peroxidation, and worsened the severity of ulcer. On the other hand, serosal blood flow was even amplified by the selective denervation of the capsaicin-sensitive vagal afferent fibers, but obestatin-induced reduction in ulcer severity was not altered. In conclusion, the gastroprotective effect of obestatin on indomethacin-induced ulcer appears to involve the activation of the vagovagal pathway.

1 December 2025 in Cardiovascular & Hematological Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GMGulsun Memi
Gulsun Memi
BYBurak Yazgan
Burak Yazgan
ETEbru Tastekin
Ebru Tastekin
Background: Chronic renal failure (CRF) triggers chronic systemic inflammation and causes vascular calcification, a prominent contributor to the progression of cardiovascular disease. Adropin and spexin peptides regulate energy balance; also, these peptides trigger anti-inflammatory pathways. Objective: Our present study aimed to clarify the potentially protective impact of spexin and adropin peptides on cardiovascular inflammation in an adenine-induced chronic renal failure model. Methods: The CRF model in Sprague-Dawley rats was established by the administration of adenine hemisulfate for ten days. Then, rats were treated with saline or adropin, or/and spexin for four weeks. CRP, CK, and CK-MB levels in serum were measured by autoanalyzer. Aortic contraction- relaxation responses were determined by the organ bath system. H&E, PAS, and Masson's trichrome stainings evaluated histopathological alterations in both aorta and cardiac tissue. Gene expression levels of ILs (IL1β, IL10, IL17A, IL18, IL21, and IL33), MMPs (MMP1, MMP2, MMP3, MMP9, MMP13, and MMP14), NGAL, TGFβ1, TIMP1, and TNFα in cardiac tissue were evaluated by real-time PCR. Results: We found increased CK and CK-MB levels by CRF induction. In addition, IL1β, IL17A, IL18, IL21, MMP1, MMP3, MMP13, and MMP14 increased after CRF progression. While adropin has effects on CK levels, spexin decreases CK-MB levels. Also, adropin and spexin had a nitric oxide-dependent impact on vascular reactivity. Besides, spexin downregulated IL1β, IL10, IL17A, TGFβ1, MMP1, MMP3, MMP9, MMP13, MMP14 and NGAL; however, the adropin peptide had a limited effect. Conclusion: These results suggest that adropin and spexin have potential preventive roles on vascular damage in CRF progression via modulation of MMPs and inflammatory genes.

1 January 2023 in Turkish Journal of Health and Sport (TJHS)
Verified
Journal Article
Closed access
GMGulsun Memi
Gulsun Memi
TGTuğba Kızıl Gül
Tuğba Kızıl Gül
DADila Şener Akçora
Dila Şener Akçora
LÖLevent Öztürk
Levent Öztürk
Background; Despite the various pharmacological agents and insulin treatment, still, there is lack of an effective and therapeutic treatment for diabetes. The present study investigated the possible therapeutic role of SPX in glucose homeostasis both functionally and structurally in streptozotocin (STZ)-induced diabetic rats. Methods; Male Wistar albino rats(n=28) were randomly divided into the control(n=4), diabetes mellitus(DM+saline;1mL/kg), DM+S10(SPX;10 µg/kg/Ml), DM+S30(SPX; 30 µg/kg/mL) and DM+S100 (SPX; 100 µg/kg/mL). Diabetes was induced by administering a single dose of STZ (35mg/kg, i.p. Blood and pancreatic tissue samples were taken for insulin level measurements by ELISA. Liver and muscle tissue samples were taken for glycogen measurement. Histopathological changes in liver, muscle and pancreas tissues were examined. Data were analyzed by ANOVA, and the Mann-Whitney-U test was used for multiple comparisons. Results; STZ-induced diabetes increased blood and urine glucose levels in the DM group as compared to the control group and significantly decreased with 10 mg/kg dose of SPX treatment. Glucose loss rate (K value) in insulin sensitivity measurements was lowered by STZ-induced diabetes (8.030) vs the control group (9.973) witha weak negative correlation (R=-0.1786). Glycogen content in liver and muscle tissues has declined, and SPX limited the decrease in hepatic glycogen levels in the DM+S10 group. SPX treatment reduced the degeneration levels and tissue damage in all tissues. Conclusions; Our findings indicated that SPX has a regulatory role in glucose homeostasis via insulin secretion, glycogen metabolism, and blood glucose regulation in a dose-dependent manner.